



# AXIM BIOTECH

---

## Company Overview

AXIM® Biotechnologies, Inc. (AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew Plus™, a CBD-based controlled release chewing gum containing 10mg of hemp-derived CBD, CanChew+ 50™, containing 50 mg of CBD undergoing clinical trials in patients with IBS, and MedChew Rx™, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy.

## AXIM® Biotechnologies Launches New Website and Management Presentation To Outline Strategic Business Initiatives

Jan 15 2019, 9:00 AM EST

## AXIM® Biotechnologies Appoints New Chief Executive Officer

Jan 8 2019, 9:00 AM EST

## New U.S. Patent Allowance Granted to AXIM® Biotechnologies for Suppository Formulations Comprised of Cannabinoids

Oct 23 2018, 9:10 AM EDT

## Stock Overview

Symbol	AXIM
Exchange	OTCQB
Market Cap	65.69m
Last Price	\$1.11
52-Week	\$0.46 - \$8.20

01/23/2019 03:48 PM EST

## Investor Relations

T: 888-759-0844  
[Investors@aximbiotech.com](mailto:Investors@aximbiotech.com)

## Management Team

### John W. Huemoeller II

Chief Executive Officer

### Dr. George E. Anastassov

Founder & Chairman of the Board

### Dr. Philip A. Van Damme, DMD MD PhD

Chief Scientific Officer

### Lekhram Changoer

Chief Technology Officer

---

## AXIM Biotechnologies, Inc.

45 Rockefeller Plaza  
20th Floor, Suite 83  
New York, NY 10111

---

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.